Lilly rides Mounjaro, Zepbound to better
Time:2024-05-01 08:03:39 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
You may also like
- Calling a female colleague a 'pretty woman' at work is sex discrimination, tribunal rules
- OJ Simpson's alma mater, USC, stays conspicuously silent on his death despite honoring the ex
- Six children dead, 14 injured in Iraq road accident
- Biden says he expects Iran to attack Israel soon, warns: 'Don't'
- A Yellowstone trip that ended with a man being arrested for kicking a bison
- Big, expensive, and not fit for purpose: What you need to know about Premier House
- Unused Auckland surgical centre could be treating more than 15,000 patients a year
- Watch live: PM Christopher Luxon talks to media in Auckland
- Former Italian foreign minister convicted for role in sale of Monte Carlo apartment